Venture Capital Shifts Toward Defensible Tech Assets in Latest Funding Roundup
A new funding roundup shows venture capital moving away from generic AI applications toward companies with proprietary assets like autonomous systems, biological data, and satellite infrastructure. Notable rounds include Tekever's $580 million Series D, Enveda's $311 million Series E, and Hubble Network's $200 million Series C. The report also notes that the definition of an 'AI company' is expanding to include drones, drug discovery, and communications infrastructure.
The funding data shows a sharp pivot in investor behavior. Physical AI companies—robotics, aerospace, and related systems—raised $47.4 billion across 521 deals in the first half of 2026, roughly quadruple the prior six-month period. Tekever's $6.4 billion valuation reflects appetite for defense hardware with manufacturing requirements and government customers, not just software wrappers.
Life sciences mirrors this trend. Enveda and Basecamp Research combined for $451 million, pairing machine learning with proprietary biological datasets and therapeutic development capabilities. Public markets are also reopening for biotech: ADARx seeks up to $1.74 billion in its U.S. IPO, while Nvidia- and QIA-backed Iambic has filed to go public after raising significant private capital.
This shift could reshape which startups receive capital and which technologies reach consumers. If investors favor companies with physical assets and proprietary data, software-only AI startups may struggle to scale, potentially slowing innovation in that segment. Defense and satellite infrastructure funding may accelerate deployment of autonomous systems in military and civilian contexts, raising questions about oversight and accountability. Healthcare applications could speed drug discovery and diagnostics, but heavy concentration of capital in a few firms may limit competition and access for smaller players.